This is particularly true in COVID-19, where sex and gender differences are reflected in significant variations in ACE2 gene expression, immune response and the pathophysiology of cardiovascular risk factors and comorbidities, contributing to lower susceptibility to infection and better survival in women and, conversely, relatively higher hospitalization and mortality rates in men. The gene discussed is ACE2; the disease is COVID-19.